source
- MapLight shares plunge 66% after mid-stage schizophrenia trial shows modest benefit but raises competitive concernsMapLight Therapeutics announced results from its mid‑stage trial of an experimental schizophrenia drug. The study enrolled adults experiencing an acute exacerbation of psychotic symptoms. The twic…
- Lilly, AbbVie and others pursue in-vivo CAR-T, but safety concerns loomAnalysts at H.C. Wainwright say safety will be the decisive factor for in‑vivo CAR‑T therapies, noting that convenience and efficacy alone will not win over investors. In‑vivo CAR‑T aims to genera…